PGY-2 Infectious Diseases Residency Director
Monica Donnelley, Pharm.D., BCPS-AS ID, AAHIVP
At UC Davis Medical Center since: 2004
Dr. Monica Donnelley is board certified in pharmacotherapy with added qualifications in infectious diseases. She is a Senior Pharmacist at UC Davis Medical Center. Dr. Donnelley began her pharmacy career at UCDMC in 2004 as an inpatient pharmacy technician during her undergraduate education. Graduating from pharmacy school in 2010, she was the recipient of the Mylan Institute Pharmacy Excellency Award and went on to complete a PGY1 Pharmacy Practice Residency and PGY2 Infectious Diseases Residency at UCDMC. Following completion of her ID PGY2 she accepted a position with UCDMC, focusing on infectious diseases and medication safety. Concurrently she also began teaching at Touro University (TU), College of Pharmacy in the Clinical Sciences track and obtained a volunteer faculty position as an assistant professor with the University of San Francisco, College of Pharmacy. In 2013 she was awarded Professor of the Year in Clinical Sciences at TU. After practicing as a pharmacist for five years Dr. Donnelley was promoted to Senior Pharmacist and in 2016 she assumed directorship of the long standing PGY2 infectious diseases residency program upon the retirement of her PGY2 residency director Cinda Christensen. Dr. Donnelley has been involved in the hospital setting since she was 13 years old when she started volunteering at Enloe Hospital in Chico, California.
Dr. Donnelley’s clinical practice focuses on the transition of inpatients to outpatient parenteral antimicrobial therapy (OPAT) and the optimizations of their therapy plans. Other areas of research include reduction of C. difficile infection rates through refinement of antimicrobial stewardship interventions. Her program strives to prepare PGY2 graduates for careers as infectious diseases pharmacy specialists and/or academia.
Donnelley, MA, Zhu, ES, Thompson, GR III. Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. Infection and Drug Resistance. Review 2016
Bui, C, Zhu, E., Donnelley, MA, Wilson, M., Morita, M., Cohen, SH., Brown, J. Antimicrobial Stewardship Programs that Target Only High-Cost, Broad-Spectrum Antimicrobials Miss Opportunities to Reduce Clostridium difficile Infections. American Journal of Infection Control. 2016
Heintz, B, Donnelley, M, Tasaka, C, Duby, J. Vancomycin. Clinical Pharmacokinetics 6th Edition. Book Chapter 22. 2016.
Donnelley, M, Heintz, B, Duby, J, Clostridium difficile infection. Pharmacotherapy Principles and Practice Study Guide: A Case Based Care. Book Chapter 4th edition. 2016.
Donnelley, M, Duby, J, Cocanour, C. Safety and Efficacy of Fidaxomicin in Patients with Clostridium Difficile Infection. Clinical Medicine Insights: Therapeutics. 2013:5 75-79. Review Paper. DOI: 10.4137/CMT.S7279.
Donnelley, M, Christensen, C, Heintz, B. Outcomes in patients discharged from an academic medical center on outpatient parenteral antimicrobial therapy (OPAT) following interventions by a multidisciplinary OPAT team. [poster] Presented at National Meeting, Infectious Diseases Society of America October 2012, San Diego, CA
Donnelley, M, Kim, J, Christensen, C, Wiedeman. Benefits of a pediatric antimicrobial stewardship program at a large academic medical center. [poster]. Making a difference in infectious diseases (MAD-ID), Orlando, Fl, 2012